331 related articles for article (PubMed ID: 33797691)
21. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
22. Early Progressing Follicular Lymphoma.
Wallace D; Casulo C
Curr Oncol Rep; 2021 Nov; 23(12):149. PubMed ID: 34797453
[TBL] [Abstract][Full Text] [Related]
23. Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
Chin CK; Nastoupil LJ
Hematol Oncol Clin North Am; 2020 Aug; 34(4):743-756. PubMed ID: 32586578
[TBL] [Abstract][Full Text] [Related]
24. Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.
Apostolidis J; Mokhtar N; Al Omari R; Darweesh M; Al Hashmi H
Hematol Oncol; 2020 Aug; 38(3):213-222. PubMed ID: 31891210
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory Agents in Follicular Lymphoma.
Ysebaert L; Morschhauser F
Hematol Oncol Clin North Am; 2020 Aug; 34(4):715-726. PubMed ID: 32586576
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in follicular lymphoma.
Flowers CR; Leonard JP; Fowler NH
Blood; 2020 Jun; 135(24):2133-2136. PubMed ID: 32236519
[TBL] [Abstract][Full Text] [Related]
27. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
28. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
29. Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
Cheson BD; Morschhauser F; Martin P
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):563-571. PubMed ID: 32303486
[TBL] [Abstract][Full Text] [Related]
30. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide: A Review in Previously Treated Follicular Lymphoma.
Blair HA
Drugs; 2020 Sep; 80(13):1337-1344. PubMed ID: 32803669
[TBL] [Abstract][Full Text] [Related]
32. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP; Trneny M; Izutsu K; Fowler NH; Hong X; Zhu J; Zhang H; Offner F; Scheliga A; Nowakowski GS; Pinto A; Re F; Fogliatto LM; Scheinberg P; Flinn IW; Moreira C; Cabeçadas J; Liu D; Kalambakas S; Fustier P; Wu C; Gribben JG;
J Clin Oncol; 2019 May; 37(14):1188-1199. PubMed ID: 30897038
[TBL] [Abstract][Full Text] [Related]
33. Pharmacology and pharmacokinetics of tazemetostat.
Orleni M; Beumer JH
Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
[TBL] [Abstract][Full Text] [Related]
34. Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.
Longley J; Johnson PWM
Curr Oncol Rep; 2021 May; 23(7):76. PubMed ID: 33937922
[TBL] [Abstract][Full Text] [Related]
35. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
[TBL] [Abstract][Full Text] [Related]
36. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
37. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S; Assouline S
Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
[TBL] [Abstract][Full Text] [Related]
38. Novel Therapy Approaches to Follicular Lymphoma.
Northend M; Townsend W
Drugs; 2021 Mar; 81(4):453-469. PubMed ID: 33616890
[TBL] [Abstract][Full Text] [Related]
39. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
40. Divergent paths: management of early relapsed follicular lymphoma.
Takiar R; Karimi Y; Phillips TJ
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):666-675. PubMed ID: 36485106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
